查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1387442

红斑治疗市场报告：到 2030 年的趋势、预测和竞争分析

Erythromelagia Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

红斑性肢痛症治疗的趋势与预测

预计 2024 年至 2030 年，全球红斑治疗市场将以 5.8% 的年复合成长率成长。该市场的主要驱动力是成红血球发育不全患者数量的增加、精准医疗投资的增加以及药物研发技术的进步。全球红斑治疗市场的未来充满希望，医院、居家医疗和专科诊所市场充满机会。

红斑治疗市场洞察

Lucintel 预测，由于可以使用有效的药物来控製成红血球发育不全的症状，因此在预测期内药物治疗将继续在该领域占据主导地位。

由于对基础设施和专业知识的需求不断增加，为红血球再生障碍患者提供全面治疗，医院仍将是该市场中最大的部分。

由于研究型大学、医学院和製药公司数量不断增加，北美仍是预测期内最大的地区。

本报告回答了 11 个关键问题：

  • Q.1. 细分市场中最有前途和高成长的机会是什么？
  • Q.2.哪个细分市场将以更快的速度成长？为什么？
  • Q.3.您认为哪些地区未来会出现更快的成长？为什么？
  • Q.4. 影响市场动态的主要因素有哪些？市场的主要挑战和商业风险是什么？
  • Q.5. 这个市场的商业风险和竞争威胁是什么？
  • Q.6.这个市场有哪些新趋势？为什么？
  • Q.7.市场客户需求有何改变？
  • Q.8. 该市场有哪些新发展以及哪些公司处于领先地位？
  • Q.9.这个市场的主要企业有哪些？主要企业采取哪些策略配合措施来发展业务？
  • Q.10. 该市场上的竞争产品有哪些？由于材料或产品替代而导致市场占有率下降的威胁有多大？
  • Q.11.过去年度发生了哪些併购事件，对产业产生了哪些影响？

目录

第1章执行摘要

第2章全球红斑治疗市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第3章2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球红斑治疗市场趋势（2018-2023）与预测（2024-2030）
  • 按治疗分類的全球红斑治疗市场
    • 药品
    • 外科手术
  • 按类型分類的全球红斑治疗市场
    • 原发性红斑疼痛
    • 续发性红斑疼痛
  • 按药物分類的全球红斑治疗市场
    • 利多卡因
    • 辣椒素
    • 双氯芬酸
    • 溴莫尼定
    • 米索前列醇
    • 其他的
  • 按最终用途分類的全球红斑治疗市场
    • 医院
    • 居家护理
    • 专科诊所
    • 其他的

第4章2018-2030年分地区市场趋势及预测分析

  • 全球红斑治疗市场（按地区）
  • 北美红斑治疗市场
  • 欧洲红斑治疗市场
  • 亚太红斑治疗市场
  • 其他区域红斑治疗市场

第5章竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第6章成长机会与策略分析

  • 成长机会分析
    • 全球红斑治疗市场按治疗方式的成长机会
    • 按类型分類的全球红斑治疗市场成长机会
    • 全球红斑治疗市场药物成长机会
    • 按最终用途分類的全球红斑治疗市场成长机会
    • 按地区分類的全球红斑治疗市场成长机会
  • 全球红斑治疗市场新趋势
  • 战略分析
    • 新产品开发
    • 扩大全球红斑治疗市场的产能
    • 全球红斑治疗市场的合併、收购与合资企业
    • 认证和许可

第7章主要企业概况

  • Teva Pharmaceutical Industries
  • Xenon
  • Biogen
  • ICAGEN
  • Pfizer
  • Zydus Cadila
  • ANI Pharmaceuticals
简介目录

Erythromelagia Treatment Trends and Forecast

The future of the global erythromelagia treatment market looks promising with opportunities in the hospital, homecare, and specialty clinic markets. The global erythromelagia treatment market is expected to grow with a CAGR of 5.8% from 2024 to 2030. The major drivers for this market are growing number of patients with erythromelalgia, rising investment in precision medicine, and advancement in drug discovery technologies.

A more than 150-page report is developed to help in your business decisions.

Erythromelagia Treatment by Segment

The study includes a forecast for the global erythromelagia treatment by treatment, type, drug, end-use, and region.

Erythromelagia Treatment Market by Treatment [Shipment Analysis by Value from 2018 to 2030]:

  • Medication
  • Surgery

Erythromelagia Treatment Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Primary Erythromelalgia
  • Secondary Erythromelalgia

Erythromelagia Treatment Market by Drug [Shipment Analysis by Value from 2018 to 2030]:

  • Lidocaine
  • Capsaicin
  • Diclofenac
  • Brimonidine
  • Misoprostol
  • Others

Erythromelagia Treatment Market by End-Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Erythromelagia Treatment Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Erythromelagia Treatment Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies erythromelagia treatment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the erythromelagia treatment companies profiled in this report include-

  • Teva Pharmaceutical Industries
  • Xenon
  • Biogen
  • ICAGEN
  • Pfizer
  • Zydus Cadila
  • ANI Pharmaceuticals

Erythromelagia Treatment Market Insights

Lucintel forecasts that medication will remain the larger segment over the forecast period due to availablilty of medications, which are effective in managing the symptoms of the disease.

Within this market, hospital will remain the largest segment due to growing need of infrastructure and expertise to provide comprehensive care for patients with erythromelalgia.

North America will remain the largest region over the forecast period due to rising number of research universities, medical schools, and pharmaceutical firms in the region.

Features of the Global Erythromelagia Treatment Market

Market Size Estimates: Erythromelagia treatment market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Erythromelagia treatment market size by various segments, such as by treatment, type, drug, end-use, and region in terms of value ($B).

Regional Analysis: Erythromelagia treatment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different treatments, types, drugs, end-uses, and regions for the erythromelagia treatment market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the erythromelagia treatment market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for erythromelagia treatment market?

Answer: The global erythromelagia treatment market is expected to grow with a CAGR of 5.8% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the erythromelagia treatment market?

Answer: The major drivers for this market are growing number of patients with erythromelalgia, rising investment in precision medicine and advancement in drug discovery technologies.

Q3. What are the major segments for erythromelagia treatment market?

Answer: The future of the erythromelagia treatment market looks promising with opportunities in the hospital, homecare, and specialty clinic markets.

Q4. Who are the key erythromelagia treatment market companies?

Answer: Some of the key erythromelagia treatment companies are as follows:

  • Teva Pharmaceutical Industries
  • Xenon
  • Biogen
  • ICAGEN
  • Pfizer
  • Zydus Cadila
  • ANI Pharmaceuticals

Q5. Which erythromelagia treatment market segment will be the largest in future?

Answer: Lucintel forecasts that medication will remain the larger segment over the forecast period due to availablilty of medications, which are effective in managing the symptoms of the disease.

Q6. In erythromelagia treatment market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to rising number of research universities, medical schools, and pharmaceutical firms in the region.

Q7. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the erythromelagia treatment market by treatment (medication and surgery), type (primary erythromelalgia and secondary erythromelalgia), drug (lidocaine, capsaicin, diclofenac, brimonidine, misoprostol, and others), end-use (hospitals, homecare, specialty clinics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Erythromelagia Treatment Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Erythromelagia Treatment Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Erythromelagia Treatment Market by Treatment
    • 3.3.1: Medication
    • 3.3.2: Surgery
  • 3.4: Global Erythromelagia Treatment Market by Type
    • 3.4.1: Primary Erythromelalgia
    • 3.4.2: Secondary Erythromelalgia
  • 3.5: Global Erythromelagia Treatment Market by Drug
    • 3.5.1: Lidocaine
    • 3.5.2: Capsaicin
    • 3.5.3: Diclofenac
    • 3.5.4: Brimonidine
    • 3.5.5: Misoprostol
    • 3.5.6: Others
  • 3.6: Global Erythromelagia Treatment Market by End-Use
    • 3.6.1: Hospitals
    • 3.6.2: Homecare
    • 3.6.3: Specialty Clinics
    • 3.6.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Erythromelagia Treatment Market by Region
  • 4.2: North American Erythromelagia Treatment Market
    • 4.2.2: North American Erythromelagia Treatment Market by End-Use: Hospitals, Homecare, Specialty Clinics, and Others
  • 4.3: European Erythromelagia Treatment Market
    • 4.3.1: European Erythromelagia Treatment Market by Treatment: Medication and Surgery
    • 4.3.2: European Erythromelagia Treatment Market by End-Use: Hospitals, Homecare, Specialty Clinics, and Others
  • 4.4: APAC Erythromelagia Treatment Market
    • 4.4.1: APAC Erythromelagia Treatment Market by Treatment: Medication and Surgery
    • 4.4.2: APAC Erythromelagia Treatment Market by End-Use: Hospitals, Homecare, Specialty Clinics, and Others
  • 4.5: ROW Erythromelagia Treatment Market
    • 4.5.1: ROW Erythromelagia Treatment Market by Treatment: Medication and Surgery
    • 4.5.2: ROW Erythromelagia Treatment Market by End-Use: Hospitals, Homecare, Specialty Clinics, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Erythromelagia Treatment Market by Treatment
    • 6.1.2: Growth Opportunities for the Global Erythromelagia Treatment Market by Type
    • 6.1.3: Growth Opportunities for the Global Erythromelagia Treatment Market by Drug
    • 6.1.4: Growth Opportunities for the Global Erythromelagia Treatment Market by End-Use
    • 6.1.5: Growth Opportunities for the Global Erythromelagia Treatment Market by Region
  • 6.2: Emerging Trends in the Global Erythromelagia Treatment Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Erythromelagia Treatment Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Erythromelagia Treatment Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Teva Pharmaceutical Industries
  • 7.2: Xenon
  • 7.3: Biogen
  • 7.4: ICAGEN
  • 7.5: Pfizer
  • 7.6: Zydus Cadila
  • 7.7: ANI Pharmaceuticals